Evolución temporal de la terapia antirretroviral (2017-2021): análisis de la modificación del tratamiento y su impacto económico

Herranz-Bayo, Elena; Navarro-Aznárez, Herminia; Pinilla-Rello, Andrea; Díaz-Calderón-Horcada, Carlos Ignacio.
Rev. esp. quimioter ; 36(6): 604-611, dec. 2023. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-228247

Documentos relacionados

  1. A meta-analysis approach for estimating average unit costs for ART using pooled facility-level primary data from African countries.
  2. Demand and Supply Motivations for Antiretroviral Drugs in Illicit Street Markets: The Case of Atlanta, Georgia.
  3. Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?
  4. Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.
  5. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.
  6. Willingness to pay for antiretroviral drugs among HIV and AIDS clients in south-east Nigeria.
  7. HIV antiretroviral medication stock-outs in Ghana: contributors and consequences.
  8. Cost and cost-effectiveness of transitioning to universal initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding women in Swaziland.
  9. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.
  10. Cost-Effectiveness of antiretroviral therapy: A systematic review.